Skip to main
SPRY

SPRY Stock Forecast & Price Target

SPRY Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ARS Pharmaceuticals is well-positioned for long-term success with its revolutionary product, neffy, and its new drug ARS-2 for chronic spontaneous urticaria (CSU) flares. While potential challenges and competition may arise, the company has taken steps to prioritize and manage its costs effectively, with a goal of reaching cash-flow breakeven by 2027 and a $1,500 per dose pricing level for ARS-2 that is sustainable and accessible to patients. With the potential for additional expansion and growth opportunities, ARS Pharmaceuticals shows strong potential for long-term profitability.

Bears say

ARS Pharmaceuticals is facing significant challenges in the market, including potential payer restrictions and slow reimbursement negotiations for their product neffy, which could limit its uptake and revenue potential. The company is actively focused on overcoming these challenges through targeted outreach, removing barriers for prescribers and patients, and pursuing favorable access for neffy, but competition from alternative non-injection epinephrine products could limit market share and profitability. Additionally, changes in leadership and uncertainties in the healthcare landscape could further impact the company's growth prospects.

SPRY has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ARS Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ARS Pharmaceuticals Inc (SPRY) Forecast

Analysts have given SPRY a Buy based on their latest research and market trends.

According to 3 analysts, SPRY has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ARS Pharmaceuticals Inc (SPRY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.